Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Double-edged Sword of Diabetes Drug Development

This article was originally published in Start Up

Executive Summary

Intense interest in new diabetes drugs gives start-ups many choices for technology development or in-licensing, but recent regulatory caution also increases risk.

Related Content

Marrying Glucagon with GLP-1 to Treat Obesity
Omentec Biosciences Inc.
Januvia: Defining Primary-Care Success and Risk
Alba Therapeutics Corp.
Alinea Pharmaceuticals Inc.
Shadow FDA? Researchers Are Taking Approval Matters into their Own Hands
Diabetica Ltd.
DiaKine Therapeutics Inc.
Will Late Loss Debate Stifle Device Start-Up Innovation?
In-licensing Drugs for Personalized Medicine: What You Know, When You Know It


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts